XBiotech XBIT,
developer of True Human(TM) therapeutic antibodies, announced today that it
has already identified positive donors for its first anti-Clostridium
difficile (C. difficile) product candidate. Just two weeks after initial
screening of blood donations from healthy volunteers, XBiotech has
identified donors that have antibody reactivity against its targeted
moieties on the C. difficile bacteria. Identifying natural antibodies
against C. difficile in the healthy population is the first step in the
discovery process for True Human therapeutic antibodies. Since it is unknown
at the onset whether or not natural antibodies will be present in the
healthy population, the Company believes that identifying these antibodies,
especially so quickly, is a good indication that they are important in
protection against disease.
John Simard, President and CEO of XBiotech, stated, "Once again, we have
demonstrated the remarkable efficiency of our True Human platform to
identify leads for the development of natural human antibodies against
disease. We look forward to now cloning the anti-C. difficile antibody
genes, and potentially advancing a lead antibody toward clinical studies.
With our C. difficile program we are attempting to do something quite
extraordinary--unlike any other marketed antibody therapy, our goal is to
develop the first oral-delivered monoclonal antibody therapy. Gut infection
with C. difficile is a dreadful disease that attacks the most vulnerable,
including the aged and infirm. An oral antibody therapy in this population
could be a very important advance. We look forward to achieving further
milestones in this program."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in